Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13330408 | 0.87 | CHRM2 (0.43) | CNR2MEN1KMT2AALDH1A1CYP3A4 | |
| SCHEMBL3307015 | 0.79 | CNR2 (0.51) | CNR2MEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL18932781 | 0.76 | CNR2 (0.46) | CNR2MEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL13330461 | 0.72 | CNR2 (0.44) | CNR2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL3313326 | 0.72 | MEN1 (0.40) | MEN1KMT2AALDH1A1CYP3A4MAPT | |
| SCHEMBL6615865 | 0.72 | CNR2 (0.42) | CNR2MEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL13330429 | 0.70 | TRPV6 (0.47) | CNR2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL9730312 | 0.69 | SMN1; SMN2 (0.41) | MEN1KMT2AALDH1A1CYP3A4MAPT | |
| SCHEMBL17323544 | 0.69 | HSD11B1 (0.41) | CNR2MEN1KMT2A | |
| SCHEMBL7121045 | 0.68 | TXNRD1 (0.41) | MEN1KMT2ASMN1; SMN2HTTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113816-A1 | METHOD FOR PREPARTION OF SUBSTITUTED ADAMANTYLARYMAGNESIUM HALIDES | JSC GRINDEKS (LV) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113816-A1 | METHOD FOR PREPARTION OF SUBSTITUTED ADAMANTYLARYMAGNESIUM HALIDES | AGL, MACROD1, MACROD2 | CNR2 1967/4885MEN1 294/4885KMT2A 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.